Avalo Therapeutics AVTX Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's quick ratio?
- Avalo Therapeutics (AVTX) reported quick ratio of 7.7× in Q1 2026.
- How has Avalo Therapeutics's quick ratio changed year-over-year?
- Avalo Therapeutics's quick ratio decreased by 66.1% year-over-year, from 22.6× to 7.7×.
- What is the long-term trend for Avalo Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Avalo Therapeutics's quick ratio has grown at a 36.6% compound annual growth rate (CAGR), from 1.7× to 8.1×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.